In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 4012-4015

  Guinea, Jesús ^a,b,c   Recio, Sandra ^a   Escribano, Pilar ^a   Peláez, Teresa ^a,b,c   Gama, Beatriz ^a   Bouza, Emilio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIPODASCUS CAPITATUS; DRUG POTENCY; FUNGAL STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHODOTORULA MUCILAGINOSA; SACCHAROMYCES CEREVISIAE; TRICHOSPORON; YEAST;

ANTIFUNGAL AGENTS; DIPODASCUS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; PYRIMIDINES; RHODOTORULA; SACCHAROMYCES CEREVISIAE; TRIAZOLES; TRICHOSPORON;

EID: 77956114534     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00685-10     Document Type: Article

References (16)

1. Reference deleted.
2. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
3. De Almeida, G. M., S. F. Costa, M. Melhem, A. L. Motta, M. W. Szeszs, F. Miyashita, L. C. Pierrotti, F. Rossi, and M. N. Burattini. 2008. Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects. Med. Mycol. 46:547-556.
4. Guinea, J., T. Peláez, L. Alcalá, and E. Bouza. 2007. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 57:273-276.
5. Guinea, J., T. Peláez, S. Recio, M. Torres-Narbona, and E. Bouza. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52:1396-1400.
6. Illnait-Zaragozi, M. T., G. F. Martínez, I. Curfs-Breuker, C. M. Fernández, T. Boekhout, and J. F. Meis. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52:1580-1582.
7. Paphitou, N. I., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46:1144-1146.
8. Pfaller, J. B., S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller. 2003. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J. Clin. Microbiol. 41:1126-1129.
9. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
10. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
11. Sancak, B., S. Alp, G. Hascelik, and S. Arikan. 2009. Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods. Mikrobiyol. Bul. 43:269-276.
12. Seifert, H., U. Aurbach, D. Stefanik, and O. Cornely. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821.
13. Thompson, G. R., III, A. W. Fothergill, N. P. Wiederhold, A. C. Vallor, B. L. Wickes, and T. F. Patterson. 2008. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 52:2959-2961.
14. Thompson, G. R., III, N. P. Wiederhold, D. A. Sutton, A. Fothergill, and T. F. Patterson. 2009. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J. Antimicrob. Chemother. 64:79-83.
15. Walsh, T. J., A. Groll, J. Hiemenz, R. Fleming, E. Roilides, and E. Anaissie. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1):48-66.
16. White, T., T. Bruns, S. Lee, and J. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.